Domingo P, Hill A, Gostkorzewicz J, Brogan A. Comparative cost-effectiveness analysis between darunavir/r and other protease inhibitors in the treatment of HIV-1 infection in naïve patients in Spain. Poster presented at the Third National GESIDA Congress; November 2011. Seville, Spain. doi: 10.1016 / j.eimc.2012.11.001
Antela A, Llibre JM, Lopez Bernaldo De Quiros JC, Portilla J, Gallois A, Campbell A, Penafiel J, Brogan AJ, Talbird SE. HIV Treatment Cost-Effectiveness Study Group. An economic model to assess the cost-effectiveness of early treatment initiation for people with HIV infection in Spain. Poster presented at the Third National GESIDA Congress; November 2011. Seville, Spain.
Deniz B, Brogan AJ, Miller JD, Talbird SE, Thompson JR. Projections using decision-analytic modeling of long-term clinical value of telaprevir for the treatment of HCV patients who had failed prior peginterferon/ribavirin treatment. Poster presented at the 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) Conference; November 2011. San Francisco, CA. [abstract] Hepatology. 2011 Oct 1; 54(Suppl. 1):802A-3A.
Deniz B, Brogan AJ, Miller JD, Talbird SE, Thompson J. Cost-effectiveness assessment of telaprevir combination treatment compared to pegylated-interferon + ribavirin alone in the management of chronic hepatitis C in patients who failed a prior pegylated-interferon + ribavirin treatment. Poster presented at the Annual Scientific Meeting of the American College of Gastroenterology; October 2011.
Brogan AJ, Talbird SE, Cohen C. Cost-effectiveness of nucleoside reverse transcriptase inhibitor pairs in efavirenz-based regimens for treatment-naïve adults with HIV infection in the United States. Value Health. 2011 Jul 1;14(5):657-554.
Aragãgo F, Vera J, Vaz Pinto I, Talbird SE, Brogan AJ. Economic evaluation of early antiretroviral treatment for HIV-1 infected individuals in Portugal. Poster presented at the 6th Annual Conference of the International AIDS Society; July 2011.
Brogan AJ, Miller JD, Talbird SE, Thompson J, Deniz B. Long-term clinical value of telaprevir for treatment of treatment-naïve and treatment-experienced patients with hepatitis C virus infection: projections using decision-analytic modeling. Poster presented at the 2011 Digestive Disease Week; May 9, 2011. Chicago, IL.
Talbird SE, Brogan AJ, Winiarski AP. Oseltamivir for influenza postexposure prophylaxis: economic evaluation for children aged 1-12 years in the U.S. Am J Prev Med. 2009 Nov 1;37(5):381-8.
Smets E, Stoll M, Hill A, Soorapanth S, Donatz V, Brogan AJ. Comparative cost-efficacy analysis of darunavir/r and other ritonavir-boosted protease inhibitors for first-line treatment of HIV-1 infection in Germany. Poster presented at the 12th European AIDS Conference/EACS; November 2009.
Smets E, Soorapanth S, Brogan AJ, Mrus J. Cost-efficacy analysis of darunavir/r vs. lopinavir/r as a first-line HIV treatment in the United States. Poster presented at the 47th Annual Meeting of the Infectious Diseases Society of America; October 2009.
Bischof M, Brogan AJ, Talbird SE, Cavassini M, Bernasconi E, Furrer H. Cost-effectiveness of the first-line antiretroviral backbone therapies in combination with efavirenz in HIV-infected patients in Switzerland. Poster presented at the 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention; July 2009. Cape Town, South Africa.
Soorapanth S, Brogan AJ, Mrus J, Smets E. Comparative cost-efficacy analysis of darunavir/r for first-line treatment of HIV infection in the US. Poster presented at the International Society for Pharmacoeconomics and Outcomes Research 14th Annual International Meeting; May 2009. [abstract] Value Health. 12(3):A112.
Brogan AJ, Everhard F, Talbird SE, Hutt E. Cost-effectiveness of tenofovir/emtricitabine in treatment naïve adults with HIV infection in the United States. Poster presented at the 21st Annual Meeting and Showcase of the American Managed Care Pharmacy; April 2009.
Talbird SE, Brogan AJ, Winiarski AP, Sander B. Cost-effectiveness of treating influenzalike illness with oseltamivir in the United States. Am J Health Syst Pharm. 2009 Mar 1;66(5):469-80.
Brogan AJ, Soorapanth S, Donatz V, Hill A, Smets E. Comparative cost-efficacy analysis of darunavir/r and other ritonavir-boosted protease inhibitors for first-line treatment of HIV-1 infection in Germany. Poster presented at the 2009 ISPOR 12th Annual European Congress; October 28, 2009. Paris, France. [abstract] Value Health. 2009; 12(7):A426.